Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 6, 2006

Gen-Probe’s Aptima HIV-1 RNA Qualitative Assay Obtained Approval for Clinical Use

  • Gen-Probe received marketing approval for the Aptima® HIV-1 RNA qualitative assay. The assay is the first FDA-approved qualitative nucleic acid test (NAT), according to the company. Aptima will aid diagnosis of acute and primary HIV-1 infection and confirm HIV-1 infection in individuals whose specimen is repeatedly reactive for HIV-1 antibodies in the clinical.

    Gen-Probe expects to launch the assay in November in conjunction with the Aptima HCV (hepatitis C virus) RNA qualitative assay.

    The Aptima HCV assay may be used to detect HCV RNA in individuals with antibody evidence of HCV infection and evidence of liver disease, individuals suspected to be actively infected with HCV with antibody evidence, and individuals at risk for HCV infection with antibodies to HCV.

    “We believe these two new qualitative viral products may fill a small yet important medical niche in the detection of two treatable but potentially life-threatening diseases, especially in light of new CDC guidelines that support increased testing for HIV and new scientific publications regarding hepatitis C,” comments Steve Kondor, vp of sales and marketing.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »